Literature DB >> 27823818

Progress in Transplantation: Will It Be Achieved in Big Steps or by Marginal Gains?

Jeremy R Chapman1.   

Abstract

A wish for progress in transplantation assumes that there are needs not met by the currently available therapy and that the barriers to resolving the problems can be surmounted. There are 5 major unmet needs: the potential to avoid transplantation either by prevention of disease or provision of an alternative to natural biological organ replacement; geographic heterogeneity of access to, and quality of, transplantation; availability of transplantation to those in need of it; survival of the patient and the transplant; and the avoidance of adverse effects of immunosuppression. During the past 50 years, there have been advances on at least 4 of these 5 fronts that illustrate the interplay of "big steps" and "marginal gains" in the following areas: surgical technique, testing the immunologic barriers, introduction of chemical and biological immunosuppression, and prophylaxis for microbial infections. The potential for further improvement comes in 5 major areas: blood biomarkers for monitoring of rejection, drug-free transplantation through the development of stable tolerance, eliminating the impact of ischemia-reperfusion injury, xenotransplantation of porcine kidneys, and finally, the possibility of autologous regeneration of functioning kidney tissue to treat advanced kidney disease.
Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Kidney transplantation; biomarkers; end-stage kidney disease; graft survival; health disparities; immunosuppression; ischemia-reperfusion injury; rejection; renal transplant; review; viral prophylaxis; xenotransplantation

Mesh:

Year:  2016        PMID: 27823818     DOI: 10.1053/j.ajkd.2016.08.024

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  9 in total

1.  HLA-G dimer targets Granzyme B pathway to prolong human renal allograft survival.

Authors:  Ashwin Ajith; Vera Portik-Dobos; Anh Thu Nguyen-Lefebvre; Christine Callaway; Daniel D Horuzsko; Rajan Kapoor; Carlos Zayas; Katsumi Maenaka; Laura L Mulloy; Anatolij Horuzsko
Journal:  FASEB J       Date:  2019-01-08       Impact factor: 5.191

2.  Serum creatinine level at 1-month posttransplant can independently predict long-term graft survival and functional status.

Authors:  Sung Min Koh; Man Ki Ju; Kyu Ha Huh; Yu Suen Kim; Myoung Soo Kim
Journal:  Korean J Transplant       Date:  2020-12-08

3.  The risk factors associated with treatment-related mortality in 16,073 kidney transplantation-A nationwide cohort study.

Authors:  Hyunji Choi; Woonhyoung Lee; Ho Sup Lee; Seom Gim Kong; Da Jung Kim; Sangjin Lee; Haeun Oh; Ye Na Kim; Soyoung Ock; Taeyun Kim; Min-Jeong Park; Wonkeun Song; John Hoon Rim; Jong-Han Lee; Seri Jeong
Journal:  PLoS One       Date:  2020-07-28       Impact factor: 3.240

4.  Frailty predicts surgical complications after kidney transplantation. A propensity score matched study.

Authors:  Milena Dos Santos Mantovani; Nyara Coelho de Carvalho; Thomáz Eduardo Archangelo; Luis Gustavo Modelli de Andrade; Sebastião Pires Ferreira Filho; Ricardo de Souza Cavalcante; Paulo Roberto Kawano; Silvia Justina Papini; Nara Aline Costa; Ricardo Augusto Monteiro de Barros Almeida
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

5.  Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients.

Authors:  Thomas Duflot; Charlotte Laurent; Anne Soudey; Xavier Fonrose; Mouad Hamzaoui; Michèle Iacob; Dominique Bertrand; Julie Favre; Isabelle Etienne; Clothilde Roche; David Coquerel; Maëlle Le Besnerais; Safa Louhichi; Tracy Tarlet; Dongyang Li; Valéry Brunel; Christophe Morisseau; Vincent Richard; Robinson Joannidès; Françoise Stanke-Labesque; Fabien Lamoureux; Dominique Guerrot; Jérémy Bellien
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

6.  The risk factors for treatment-related mortality within first three months after kidney transplantation.

Authors:  Ye Na Kim; Do Hyoung Kim; Ho Sik Shin; Sangjin Lee; Nuri Lee; Min-Jeong Park; Wonkeun Song; Seri Jeong
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

Review 7.  HLA-G and humanized mouse models as a novel therapeutic approach in transplantation.

Authors:  Ashwin Ajith; Vera Portik-Dobos; Daniel D Horuzsko; Rajan Kapoor; Laura L Mulloy; Anatolij Horuzsko
Journal:  Hum Immunol       Date:  2020-02-21       Impact factor: 2.850

8.  Pretransplant Serum Uromodulin and Its Association with Delayed Graft Function Following Kidney Transplantation-A Prospective Cohort Study.

Authors:  Stephan Kemmner; Christopher Holzmann-Littig; Helene Sandberger; Quirin Bachmann; Flora Haberfellner; Carlos Torrez; Christoph Schmaderer; Uwe Heemann; Lutz Renders; Volker Assfalg; Tarek M El-Achkar; Pranav S Garimella; Jürgen Scherberich; Dominik Steubl
Journal:  J Clin Med       Date:  2021-06-11       Impact factor: 4.241

9.  Humanized Mouse Model as a Novel Approach in the Assessment of Human Allogeneic Responses in Organ Transplantation.

Authors:  Ashwin Ajith; Laura L Mulloy; Md Abu Musa; Valia Bravo-Egana; Daniel David Horuzsko; Imran Gani; Anatolij Horuzsko
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.